FDA recall record

Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg) recall — FDA D-0290-2025

Super-Potent Drug: Out of specification potency results were obtained.

Class IIclassification
D-0290-2025official record ID
Mar 26, 2025report date

Recall record at a glance

Official recordD-0290-2025
CategoryDrug Recalls
ClassificationClass II
FDA record statusOngoing
Recalling firmMylan Institutional, Inc.
Report dateMar 26, 2025
Recall initiation dateMar 7, 2025
Quantity347 Cartons
LocationRockford, IL, United States

Official product description

Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), Rx Only, 100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each) per carton, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 51079-445-20.

Why the product was recalled

Super-Potent Drug: Out of specification potency results were obtained.

Distribution information

Nationwide in the USA

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.